Bioelectronica nabs financing to advance antibody discovery platform

By The Science Advisory Board staff writers

February 8, 2021 -- Proxima Ventures and Co-win Ventures have invested in Bioelectronica to advance the company's digital biochemistry innovations, including novel assay development and electrofluidics.

Bioelectronica will use the series A financing to expand its team, drive new applications in cell line development, and further antibody discovery for the Hypercell platform. The capital will also be used for scaling the numbers of clients served through product sales of Hypercell, custom assay development, and contract research.

Hypercell is the company's proprietary single-cell sorting system that uses computer vision, data science, and lensless imaging to enable single-cell sorting assays with high throughput. Bioelectronica is using the platform to identify productive cells in antibody discovery and accelerate development with its computer vision single-cell sorting system.

Copyright © 2021

Infectious Diseases (ID) Week 2021
September 29 - October 3
San Diego, California United States
Imaging Mass Spectrometry Society (IMSS) 3 in 2021
October 3-6
Colorado Springs, Colorado United States
Cell & Gene Meeting on the Mesa
October 10-14
Carlsbad, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter